Insider Selling: Keryx Biopharmaceuticals (KERX) General Counsel Sells 5,652 Shares of Stock

Keryx Biopharmaceuticals (NASDAQ:KERX) General Counsel Brian Adams sold 5,652 shares of Keryx Biopharmaceuticals stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $4.81, for a total transaction of $27,186.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Brian Adams also recently made the following trade(s):

  • On Monday, January 29th, Brian Adams sold 1,541 shares of Keryx Biopharmaceuticals stock. The shares were sold at an average price of $4.81, for a total transaction of $7,412.21.
  • On Friday, January 5th, Brian Adams sold 753 shares of Keryx Biopharmaceuticals stock. The shares were sold at an average price of $4.69, for a total transaction of $3,531.57.

Shares of Keryx Biopharmaceuticals (KERX) opened at $4.89 on Friday. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95. Keryx Biopharmaceuticals has a 12 month low of $4.01 and a 12 month high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). The company had revenue of $18.70 million during the quarter, compared to the consensus estimate of $17.53 million. Keryx Biopharmaceuticals had a negative return on equity of 2,494.37% and a negative net margin of 269.52%. The firm’s quarterly revenue was up 96.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.32) EPS. equities analysts expect that Keryx Biopharmaceuticals will post -0.61 EPS for the current fiscal year.

A number of research firms have recently issued reports on KERX. Morgan Stanley dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 8th. ValuEngine lowered shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Stifel Nicolaus dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.19.

Large investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC increased its stake in shares of Keryx Biopharmaceuticals by 3.6% in the second quarter. TIAA CREF Investment Management LLC now owns 220,336 shares of the biopharmaceutical company’s stock worth $1,593,000 after buying an additional 7,576 shares during the last quarter. Gotham Asset Management LLC bought a new stake in shares of Keryx Biopharmaceuticals in the second quarter worth $402,000. Schwab Charles Investment Management Inc. increased its stake in shares of Keryx Biopharmaceuticals by 1.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock worth $3,190,000 after buying an additional 4,388 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Keryx Biopharmaceuticals by 5.1% in the second quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after buying an additional 349,521 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Keryx Biopharmaceuticals by 39.2% in the second quarter. Alliancebernstein L.P. now owns 191,650 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 54,010 shares during the last quarter. Institutional investors and hedge funds own 63.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Keryx Biopharmaceuticals (KERX) General Counsel Sells 5,652 Shares of Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/insider-selling-keryx-biopharmaceuticals-kerx-general-counsel-sells-5652-shares-of-stock.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply